Characterizing Prostate Tumor Mouse Xenografts with CEST and MT-MRI and Redox Scanning
Characterizing Prostate Tumor Mouse Xenografts with CEST and MT-MRI and Redox Scanning
复制标题
DOI：
10.1007/978-1-4614-4989-8_6
复制
发表时间：
2013-01-01
期刊：
影响因子：
--
通讯作者：
Li, Lin Z.
中科院分区：
文献类型：
--
作者：
Cai, Kejia;Xu, He N.;Li, Lin Z.
本研究的主要目标是利用多模态成像方法揭示前列腺癌的异质性，并寻找特征异质性与肿瘤侵袭性之间的相关性。在这里，我们报告了两种侵袭性人类前列腺肿瘤系（DU-145和PC-3）异种移植到无胸腺裸鼠中的化学交换饱和转移（CEST）和磁化转移（MT）磁共振成像（MRI）和氧化还原扫描[低温NADH/Fp（还原烟酰胺腺嘌呤二核苷酸/氧化黄素蛋白）荧光成像]的初步数据。通过这些方法获得的结果似乎是一致的，所有结果都显示出 DU-145 肿瘤中的异质性水平高于 PC-3 肿瘤中的异质性。 DU-145 肿瘤显示 CEST 图具有阳性和阴性区域，而 PC-3 CEST 图相对均匀。在 CEST 不对称曲线峰值 (+2 ppm) 处，PC-3 的平均 CEST 值 (23.0 +/- 2.1 %) 明显高于 DU-145 (1.9 +/- 6.7 %) (p < 0.05)。 Fp 氧化还原比 (Fp/(NADH + Fp)) 图像显示 DU-145 肿瘤中局部高度氧化的区域，而 PC-3 肿瘤似乎异质性较低。这些结果表明代谢在肿瘤进展中可能发挥作用。未来将进行更多的研究，包括惰性前列腺肿瘤系和更大样本量的研究，以确定前列腺肿瘤侵袭性的生物标志物。
The main goal of this study was to use multimodality imaging methods to reveal the heterogeneity in prostate cancer and seek the correlation between the characteristic heterogeneity and tumor aggressiveness. Here we report the preliminary data on chemical exchange saturation transfer (CEST) and magnetization transfer (MT) magnetic resonance imaging (MRI) and redox scanning [cryogenic NADH/Fp (reduced nicotinamide adenine dinucleotide/oxidized flavoproteins) fluorescence imaging] of two aggressive human prostate tumor lines (DU-145 and PC-3) xenografted in athymic nude mice. The results obtained by these methods appeared to be consistent, with all showing a higher level of heterogeneity in DU-145 tumors than in PC-3 tumors. DU-145 tumors showed CEST maps with both positive and negative areas while PC-3 CEST maps were relatively homogeneous. The mean CEST value for PC-3, 23.0 +/- 2.1 %, is at a significantly higher level (p < 0.05) than DU-145 (1.9 +/- 6.7 %) at the peak of the CEST asymmetric curve (+2 ppm). Fp redox ratio (Fp/(NADH + Fp)) images exhibited localized highly oxidized regions in DU-145 tumors, whereas PC-3 tumors appeared to be less heterogeneous. These results suggest a possible role of metabolism in tumor progression. More studies, including an indolent prostate tumor line and with larger sample size, will be performed in the future to identify the biomarkers for prostate tumor aggressiveness.